These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15064342)

  • 1. In vitro verification of antithrombotic effect of recombinant soluble nucleotide triphosphate diphosphohydrolase 1.
    Sampram ES; Ouriel K
    J Vasc Interv Radiol; 2004 Apr; 15(4):379-84. PubMed ID: 15064342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.
    Gayle RB; Maliszewski CR; Gimpel SD; Schoenborn MA; Caspary RG; Richards C; Brasel K; Price V; Drosopoulos JH; Islam N; Alyonycheva TN; Broekman MJ; Marcus AJ
    J Clin Invest; 1998 May; 101(9):1851-9. PubMed ID: 9576748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.
    Marcus AJ; Broekman MJ; Drosopoulos JH; Pinsky DJ; Islam N; Maliszewsk CR
    Ital Heart J; 2001 Nov; 2(11):824-30. PubMed ID: 11770867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.
    Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Alyonycheva TN; Safier LB; Hajjar KA; Posnett DN; Schoenborn MA; Schooley KA; Gayle RB; Maliszewski CR
    J Clin Invest; 1997 Mar; 99(6):1351-60. PubMed ID: 9077545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model.
    Buergler JM; Maliszewski CR; Broekman MJ; Kaluza GL; Schulz DG; Marcus AJ; Raizner AE; Kleiman NS; Ali NM
    J Thromb Thrombolysis; 2005 Apr; 19(2):115-22. PubMed ID: 16052302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment.
    Drosopoulos JH; Broekman MJ; Islam N; Maliszewski CR; Gayle RB; Marcus AJ
    Biochemistry; 2000 Jun; 39(23):6936-43. PubMed ID: 10841775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
    Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
    Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury.
    Guckelberger O; Sun XF; Sévigny J; Imai M; Kaczmarek E; Enjyoji K; Kruskal JB; Robson SC
    Thromb Haemost; 2004 Mar; 91(3):576-86. PubMed ID: 14983235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
    Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
    J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
    Scazziota A; Altman R; Rouvier J; Gonzalez C; Ahmed Z; Jeske WP; Walenga JM; Fareed J
    Thromb Res; 2000 Dec; 100(6):479-88. PubMed ID: 11152927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.
    Marcus AJ; Broekman MJ; Drosopoulos JH; Olson KE; Islam N; Pinsky DJ; Levi R
    Semin Thromb Hemost; 2005 Apr; 31(2):234-46. PubMed ID: 15852226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.
    Sashindranath M; Dwyer KM; Dezfouli S; Selan C; Crikis S; Lu B; Yuan Y; Hickey MJ; Peter K; Robson SC; Cowan PJ; Nandurkar HH
    Purinergic Signal; 2017 Jun; 13(2):259-265. PubMed ID: 28343356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.
    Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Pinsky DJ; Sesti C; Levi R
    J Pharmacol Exp Ther; 2003 Apr; 305(1):9-16. PubMed ID: 12649347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?
    Hohmann JD; Wang X; Krajewski S; Selan C; Haller CA; Straub A; Chaikof EL; Nandurkar HH; Hagemeyer CE; Peter K
    Blood; 2013 Apr; 121(16):3067-75. PubMed ID: 23380744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism.
    Kaneider NC; Egger P; Dunzendorfer S; Noris P; Balduini CL; Gritti D; Ricevuti G; Wiedermann CJ
    Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):894-900. PubMed ID: 12067895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.